A great first day at #HYBRID2024! This morning, after an introduction by Bruno Bonnel, General Secretary for #Investment, we had the privilege of exploring new generations of vectors for gene therapy, as well as genome-editing strategies using Crispr Cas9. The round table addressed in depth the issue of gene therapy toxicity, as well as the costs and specificities of clinical trials for rare diseases, highlighting new clinical trial methodologies. After a lively B2B session, the second session focused on RNA as a therapeutic tool. Chantal Pichon and Pierre Wils guided us through 30 years of #research, from first observation to vaccine development. Nathalie Mignet and Philippe Barthélemy presented promising new approaches to the use of nucleic acids, opening up new strategies for combating antibiotic resistance. A fascinating and instructive day that paves the way for new advances in gene and cell therapy. Can’t wait for the rest of #HYBRID2024, we look forward to seeing you tomorrow for the 2nd day! Thomas Lombes, Thierry Hulot, Marc Bonneville, Rosalie MAURISSE, Oumeya (Mia) Adjali, Ana Buj Bello, Alexis Duvergé, Maria Grazia B., Annarita Miccio, Aurélie Bedel, Stephane Boissel, Sitra Tauscher-Wisniewski, MD, Anne DOUAR, Paul Nioi, Anette Sommer, Hélène Tran.
